Creates a new tax subchapter for “economically distressed zones” (details of the subchapter were not provided) and makes those tax changes effective for taxable years beginning after December 31, 2024. It also broadens health law authorities to identify and prioritize “population health products” — drugs and therapeutics for people with non‑communicable (chronic) conditions who face worse outcomes during pandemics — expands what counts as a qualified countermeasure, directs HHS to accelerate R&D, manufacturing, distribution and stockpiling for those products, and requires a report to Congress within 90 days on needs and incentives.